New hope for rare blood cancer: drug combo aims to keep lymphoma at bay
NCT ID NCT06947967
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 34 times
Summary
This study tests whether adding tucidinostat to standard chemotherapy (CHOP) helps people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer growing or coming back. About 224 adults newly diagnosed with this lymphoma will receive either tucidinostat or a placebo plus CHOP. The goal is to improve disease control, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL, PERIPHERAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.